vTv Therapeutics (VTVT) EV to EBIT (2015 - 2026)

vTv Therapeutics has disclosed EV to EBIT across 12 years of filings, most recently posting 27.32 for Q2 2026.

• In Q2 2026, EV to EBIT fell 190.84% year-over-year to 27.32; the TTM figure through Jun 2026 stood at 41.14 (down 1353.3% YoY), while the FY2025 annual figure was 7.56, down 306.39% from the prior year.
• EV to EBIT came in at 27.32 for Q2 2026 at vTv Therapeutics, down from 16.94 in the prior quarter.
• In the past five years, EV to EBIT ranged from a high of 16.94 in Q1 2026 to a low of 31.44 in Q4 2025.
• Average EV to EBIT over 5 years is 11.28, with a median of 10.18 recorded in 2022.
• Year-over-year, EV to EBIT plunged 242.1% in 2025 and soared 231.31% in 2026.
• Over 5 years, EV to EBIT stood at 11.63 in 2022, then jumped by 50.23% to 5.79 in 2023, then tumbled by 58.84% to 9.19 in 2024, then sank by 242.1% to 31.44 in 2025, then gained by 13.11% to 27.32 in 2026.
• Per Business Quant data, the three most recent EV to EBIT figures were 27.32 in Q2 2026, 16.94 in Q1 2026, and 31.44 in Q4 2025.